Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04958811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2026 → Nov 2026
See other at-risk trials from Georgetown University

Record History

  1. Primary completion pushed from Jul 2026 to Nov 2026 Completion pushed from Dec 2026 to Dec 2027v13 Show 1 more changeShow less
    • Completion pushed from Dec 2026 to Dec 2027
  2. Primary completion date: Dec 2025 to Jul 2026 Completion date: Dec 2025 to Dec 2026v12 Show 1 more changeShow less
    • Completion date: Dec 2025 to Dec 2026
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 42 to confirmed 29 · Site details revised at 2 of 2 sitesv11 Show 2 more changesShow less
    • Enrollment target: estimated 42 to confirmed 29
    • Site details revised at 2 of 2 sites
  4. Site contacts updated at 1 of 2 sitesv10
  5. Primary and study completion dates: Dec 2024 to Dec 2025v9
Show 7 earlier versionsHide 7 earlier versions
  1. Primary and study completion dates: Jul 2024 to Dec 2024v8
  2. Primary completion date: Jul 2023 to Jul 2024 Study sites: 1 to 2v7 Show 1 more changeShow less
    • Study sites: 1 to 2
  3. Eligibility criteria revisedv6 See this version in full on ClinicalTrials.gov ↗
  4. Start date changed from estimate of Dec 2021 to Dec 21, 2021v5
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Oct 2021 to Dec 2021 · Site details revisedv4 Show 2 more changesShow less
    • Start date: Oct 2021 to Dec 2021
    • Site details revised
  6. Start date: Jul 2021 to Oct 2021v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
Trial Details
NCT Number NCT04958811
Lead Sponsor Georgetown University
Collaborators: Genentech, Inc.
Conditions Non-squamous Non-small-cell Lung Cancer
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov